National health insurance should cover new anti-platelet drug, says professor
Published: 2012-02-17 06:56:00
Updated: 2012-02-17 06:56:00
To reduce the mortality rate of thrombotic cardiovascular (CV) events within 12 months in patients with acute coronary syndrome (ACS), the national health insurance needs to cover Brilinta (ticagrelor), a new platelet aggregation inhibitor produced by AstraZeneca.
Professor Chang Yang-su of Yo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
